- Home
- FTAI vs INCY Comparison
FTAI vs INCY Comparison
Compare FTAI & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTAI | INCY |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 17.0B |
| IPO Year | 2015 | 1993 |
Fundamental Metrics
Financial Performance| Metric | FTAI | INCY |
|---|---|---|
| Price | $173.72 | $100.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 21 |
| Target Price | ★ $201.00 | $94.94 |
| AVG Volume (30 Days) | 712.9K | ★ 2.1M |
| Earning Date | 10-27-2025 | 02-09-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ 3878.02 |
| EPS | 4.36 | ★ 5.90 |
| Revenue | $2,344,200,000.00 | ★ $4,813,105,000.00 |
| Revenue This Year | $50.33 | $19.59 |
| Revenue Next Year | $25.31 | $10.80 |
| P/E Ratio | $39.94 | ★ $16.96 |
| Revenue Growth | ★ 51.35 | 18.09 |
| 52 Week Low | $75.06 | $53.56 |
| 52 Week High | $194.36 | $109.28 |
Technical Indicators
Market Signals| Indicator | FTAI | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 55.29 | 51.22 |
| Support Level | $162.07 | $97.01 |
| Resistance Level | $184.12 | $103.45 |
| Average True Range (ATR) | 5.51 | 2.84 |
| MACD | -0.17 | 0.15 |
| Stochastic Oscillator | 57.43 | 64.78 |
Price Performance
Historical ComparisonAbout FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is an aerospace company. It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft, which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.